Insider Trading July 8, 2026 06:12 PM

Sezzle CFO Executes Pre-Arranged Sale Amid Stock Surge

Brading Lee Dickson liquidates portion of holdings under Rule 10b5-1 plan as Sezzle trades near 52-week high.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SEZL

Sezzle Inc. (NASDAQ: SEZL) Chief Financial Officer Brading Lee Dickson executed a sale of 100 shares on July 6, 2026, under a pre-existing trading plan. The transaction occurred as the company's stock reached its 52-week high, prompting mixed analyst reactions and heightened market scrutiny regarding valuation and legal developments.

Sezzle CFO Executes Pre-Arranged Sale Amid Stock Surge
SEZL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CFO Brading Lee Dickson sold 100 shares at $185 per share under a Rule 10b5-1 plan adopted in June 2025.
  • Sezzle shares traded near their 52-week high of $185, marking a 164% year-to-date return.
  • Analyst sentiment is mixed, with Needham raising its target to $166 while Oppenheimer downgraded the stock to Perform.

Brading Lee Dickson, serving as the Chief Financial Officer for Sezzle Inc. (NASDAQ: SEZL), completed a transaction to sell 100 shares of the company's common stock on July 6, 2026. The sale was executed at a price of $185 per share, resulting in a total transaction value of $18,500.

According to filings, this sale was carried out under the guidelines of a Rule 10b5-1 trading plan. Mr. Dickson originally adopted this plan on June 17, 2025. Following the completion of this transaction, his direct holdings in Sezzle common stock stand at 296,831 shares.

The timing of this sale coincides with Sezzle shares trading near their 52-week high of $185. The stock has delivered a substantial 164% return year-to-date. Despite this performance, analysis from InvestingPro indicates that the stock is currently overvalued relative to its Fair Value. Subscribers to InvestingPro have access to 13 additional exclusive tips and comprehensive Pro Research Reports covering Sezzle and over 1,400 other US equities.

In the broader investment community, Sezzle has been the subject of recent analyst actions. Needham raised its price target for Sezzle to $166 while maintaining a Buy rating. This adjustment followed investor meetings with company executives. Conversely, Oppenheimer downgraded Sezzle to Perform from Outperform, citing valuation concerns after the stock's significant price increase.

Additionally, Freedom Capital initiated coverage of Sezzle with a Hold rating. They set a price target of $150, highlighting the ongoing evolution of the Buy Now Pay Later sector. Options trading for Sezzle also saw a notable increase, with attention focused on July call options, particularly the $190 call.

On the legal front, the United States District Court for the District of Minnesota partly advanced Sezzle's antitrust claims against Shopify. The court allowed claims related to monopolization and unlawful restraint of trade to proceed. These developments reflect ongoing interest and activity surrounding Sezzle in the investment community.

Market data indicates that SEZL closed at 167.32, down 10.31 or 5.80%. After hours trading showed a 0.00% change. The stock's performance has been closely watched, with questions raised about whether SEZL presents a better opportunity compared to other equities like Siemens Energy or Sandisk, which have shown significant returns.

Risks

  • Valuation concerns have prompted Oppenheimer to downgrade Sezzle to Perform from Outperform.
  • Legal proceedings regarding antitrust claims against Shopify are ongoing, with the court partially advancing these claims.
  • Analyst coverage varies, with Freedom Capital initiating with a Hold rating and a $150 price target.

More from Insider Trading

Palisade Bio Director Robert Baltera Jr. Expands Stake with $102K Share Purchase Jul 8, 2026 Palisade Bio Executive Offloads Shares to Meet Tax Obligations Amid Clinical Milestones Jul 8, 2026 Palisade Bio Leadership Executes Strategic Stock Transactions Amid Clinical Milestones Jul 8, 2026 AppLovin Director Maynard Webb Executes $1.6M Stock Sale Under Pre-Arranged Plan Jul 8, 2026 Contineum Therapeutics CEO Stengone Executes $40,000 Share Sale Under Pre-Arranged Plan Jul 8, 2026